Abstract | BACKGROUND: METHODS: RESULTS: The study was terminated because of three treatment-related deaths when 55 patients had been enrolled (mortality rate above 5 per cent). Two deaths were due to myelosuppression and one to postoperative complications. Clinical response and R0 resection rates were 55 and 65 per cent respectively. The pathological response rate was 15 per cent. Median overall survival was 14.6 months and the 3-year survival rate 27 per cent. CONCLUSION: This multimodal treatment of locally advanced gastric cancer provides reasonable 3-year survival compared with historical data, but at a considerable cost in terms of morbidity and mortality.
|
Authors | T Yoshikawa, M Sasako, S Yamamoto, T Sano, H Imamura, K Fujitani, H Oshita, S Ito, Y Kawashima, N Fukushima |
Journal | The British journal of surgery
(Br J Surg)
Vol. 96
Issue 9
Pg. 1015-22
(Sep 2009)
ISSN: 1365-2168 [Electronic] England |
PMID | 19644974
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | (c) 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. |
Chemical References |
- Irinotecan
- Cisplatin
- Camptothecin
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Camptothecin
(administration & dosage, adverse effects, analogs & derivatives)
- Chemotherapy, Adjuvant
- Cisplatin
(administration & dosage, adverse effects)
- Epidemiologic Methods
- Female
- Gastrectomy
(mortality)
- Humans
- Irinotecan
- Lymph Node Excision
- Lymphatic Metastasis
- Male
- Middle Aged
- Stomach Neoplasms
(drug therapy, mortality, surgery)
- Treatment Outcome
|